Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (NCT01922102) | Novartis Pharmaceuticals | 2013-09-11 |
Track Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM) automatically
Every clearance here is in the API, with alerts when new ones post.